ES2902879T3 - Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones - Google Patents

Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones Download PDF

Info

Publication number
ES2902879T3
ES2902879T3 ES13731071T ES13731071T ES2902879T3 ES 2902879 T3 ES2902879 T3 ES 2902879T3 ES 13731071 T ES13731071 T ES 13731071T ES 13731071 T ES13731071 T ES 13731071T ES 2902879 T3 ES2902879 T3 ES 2902879T3
Authority
ES
Spain
Prior art keywords
tumor
cells
stained
density
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13731071T
Other languages
English (en)
Spanish (es)
Inventor
Jérôme Galon
Franck Pagès
Bernhard Mlecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Paris filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES2902879T3 publication Critical patent/ES2902879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES13731071T 2012-06-14 2013-06-14 Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones Active ES2902879T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (1)

Publication Number Publication Date
ES2902879T3 true ES2902879T3 (es) 2022-03-30

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13731071T Active ES2902879T3 (es) 2012-06-14 2013-06-14 Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones

Country Status (13)

Country Link
US (1) US10317408B2 (enExample)
EP (1) EP2861986B1 (enExample)
JP (1) JP6449765B2 (enExample)
KR (1) KR102179848B1 (enExample)
CN (1) CN104541167B (enExample)
AU (1) AU2013276470B2 (enExample)
BR (1) BR112014031143B8 (enExample)
CA (1) CA2873278C (enExample)
DE (1) DE13731071T1 (enExample)
ES (1) ES2902879T3 (enExample)
IL (1) IL235738B (enExample)
SG (1) SG11201408107RA (enExample)
WO (1) WO2013186374A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2701092T5 (es) 2014-02-24 2022-05-12 Ventana Med Syst Inc Procedimientos, kits y sistemas para puntuar la respuesta inmunitaria al cáncer por detección simultánea de CD3, CD8, CD20 y FOXP3
EP3195191B1 (en) * 2014-09-03 2020-10-21 Ventana Medical Systems, Inc. Systems and methods for calculating immune scores
CN107109459A (zh) * 2014-11-05 2017-08-29 加利福尼亚大学董事会 用于分层对阻断pd1/pdl1轴的疗法的无响应者的方法
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
CN113671186A (zh) * 2015-10-23 2021-11-19 诺华股份有限公司 对包含肿瘤组织的样品评分的方法
MX393482B (es) * 2016-05-09 2025-03-24 Inst Nat Sante Rech Med Metodos para clasificar pacientes con un cancer solido
US11315240B2 (en) * 2016-05-18 2022-04-26 Hoffmann-La Roche Inc. System and method of tumor classification
WO2018027223A1 (en) * 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
EP3532984B1 (en) * 2016-10-27 2024-05-08 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
WO2019149817A1 (en) 2018-01-31 2019-08-08 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
EP3921648A1 (en) * 2019-02-05 2021-12-15 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
US20220236276A1 (en) 2019-06-03 2022-07-28 Inserm (Institut National De La Santé Et De La Recherch Médicale Methods for modulating a treatment regimen
AU2020378280A1 (en) 2019-11-07 2022-04-07 Feng Biosciences, Ltd. Classification of tumor microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
EP4172628A1 (en) * 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
WO2023018085A1 (ko) * 2021-08-10 2023-02-16 주식회사 루닛 병리 슬라이드 이미지와 관련된 정보를 출력하는 방법 및 장치
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501184A (ja) * 1995-11-30 2000-02-02 クロマビジョン メディカル システムズ,インコーポレイテッド 生体標本の自動画像分析の方法および装置
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1969338B1 (en) * 2005-12-19 2016-08-24 Ventana Medical Systems, Inc. Automated label printing for tissue specimen slides
CA2737116C (en) * 2008-09-16 2019-01-15 Historx, Inc. Reproducible quantification of biomarker expression
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
KR20150023760A (ko) 2015-03-05
BR112014031143A2 (pt) 2017-08-08
SG11201408107RA (en) 2015-01-29
BR112014031143B8 (pt) 2022-11-22
JP6449765B2 (ja) 2019-01-09
CN104541167B (zh) 2018-05-01
AU2013276470A1 (en) 2014-11-27
US20150153349A1 (en) 2015-06-04
AU2013276470B2 (en) 2018-06-07
DE13731071T1 (de) 2016-08-18
US10317408B2 (en) 2019-06-11
EP2861986A1 (en) 2015-04-22
JP2015525349A (ja) 2015-09-03
BR112014031143B1 (pt) 2022-03-03
KR102179848B1 (ko) 2020-11-17
CA2873278A1 (en) 2013-12-19
CA2873278C (en) 2021-10-26
IL235738B (en) 2019-02-28
EP2861986B1 (en) 2021-11-10
CN104541167A (zh) 2015-04-22
IL235738A0 (en) 2015-01-29
WO2013186374A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ES2902879T3 (es) Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones
JP6405319B2 (ja) 乳癌予知のための画像分析
CA2604317C (en) Methods and system for validating sample images for quantitative immunoassays
Braun et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system
ES2542106T3 (es) Método para preparar videomicroscopía cuantitativa y sistema asociado
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
EP3117259B1 (en) Assessment of staining quality
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
KR20150023808A (ko) 조직 절편 내 단일 세포에서의 마커 정량
Halama et al. Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps
Jing et al. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer
Asogan et al. Concordance between core needle biopsy and surgical specimen for ER, PgR and Her2neu receptor status in breast cancer and study of difference in reliability between the two groups with the change in ASCO/CAP guidelines
Mittal et al. Evaluation of KI-67 Index as a Prognostic Marker in Different Molecular Subtype in Patients of Carcinoma Breast
Hasan Evaluation of cell line-derived xenografted tumors as controls for immunohistochemical testing for estrogen receptors and progesterone receptors